Business
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expected in Q1 2022Accelerated plans to evaluate NTLA-2001 for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) On track to initiate first-in-human studies of NTLA-2002 for hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia (AML) by year-end Announces nomination of NTLA-3001, its first gene insertion development candidate, for alpha-1 antitrypsin deficiency (AATD); concurrently, Regeneron and Intellia have selected a Factor 9 gene insertion development candidate to advance for hemophilia B (Hem B) Presented new data on its proprietary and differentiated allogeneic cell engineering platform and ex vivo LNP-based delivery of CRISPR/Cas9 to T cells at ESGCT Annual Congress Ended the quarter with strong cash position of $1.1 billion CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported financial results for the third quarter ended September 30, 2021, and recent operational highlights. “Intellia continues to make important progress toward advancing its full-spectrum genome editing pipeline. Today, we are pleased to share that we remain highly encouraged by the safety profile, consistency of TTR reduction and ongoing effect of NTLA-2001 in the Phase 1 study. We believe we are closing in on identifying the recommended therapeutic dose for NTLA-2001 in patients with ATTR amyloidosis with polyneuropathy for further evaluation in Part 2, a single-dose expansion cohort. Additionally, while it has long been our plan to develop NTLA-2001 for all forms of ATTR amyloidosis, we have decided to accelerate the evaluation of NTLA-2001 in patients with ATTR amyloidosis whose primary clinical manifestation is cardiomyopathy. Based on the strength of our interim dataset, we are now seeking regulatory feedback for inclusion of the ATTR-CM patient population in our current Phase 1 study. We look forward to sharing updates from this program in Q1 2022,” said Intellia President and Chief Executive Officer John Leonard, M.D. “Beyond our lead program, we remain focused ...